Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background: Overconsumption of dietary sugars, fructose in particular, is linked to cardiovascular risk factors such as type 2 diabetes, obesity, dyslipidemia and nonalcoholic fatty liver disease. However, clinical studies have to date not clarified whether these adverse cardiometabolic effects are induced directly by dietary sugars, or whether they are secondary to weight gain. Objectives: To assess the effects of fructose (75 g day−1), served with their habitual diet over 12 weeks, on liver fat content and other cardiometabolic risk factors in a large cohort (n = 71) of abdominally obese men. Methods: We analysed changes in body composition, dietary intake, an extensive panel of cardiometabolic risk markers, hepatic de novo lipogenesis (DNL), liver fat content and postprandial lipid responses after a standardized oral fat tolerance test (OFTT). Results: Fructose consumption had modest adverse effects on cardiometabolic risk factors. However, fructose consumption significantly increased liver fat content and hepatic DNL and decreased β‐hydroxybutyrate (a measure of β‐oxidation). The individual changes in liver fat were highly variable in subjects matched for the same level of weight change. The increase in liver fat content was significantly more pronounced than the weight gain. The increase in DNL correlated positively with triglyceride area under the curve responses after an OFTT. Conclusion: Our data demonstrated adverse effects of moderate fructose consumption for 12 weeks on multiple cardiometabolic risk factors in particular on liver fat content despite only relative low increases in weight and waist circumference. Our study also indicates that there are remarkable individual differences in susceptibility to visceral adiposity/liver fat after real‐world daily consumption of fructose‐sweetened beverages over 12 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069
Sugar consumption, metabolic disease and obesity: The state of the controversy
Stanhope, K. L. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1084990 · Cited by 739
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
Softic, S., Cohen, D. E., & Kahn, C. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4054-0 · Cited by 709
Ryysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H. (2000) · Diabetes · doi:10.2337/diabetes.49.5.749 · Cited by 431
Rosqvist, F., Iggman, D., Kullberg, J., Cedernaes, J., Johansson, H.-E., Larsson, A., Johansson, L., Ahlström, H., Arner, P., Dahlman, I., et al. (2014) · Diabetes · doi:10.2337/db13-1622 · Cited by 429
Fructose and Cardiometabolic Health
Malik, V. S., & Hu, F. B. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.025 · Cited by 408
Aeberli, I., Gerber, P. A., Hochuli, M., Kohler, S., Haile, S. R., Gouni-Berthold, I., Berthold, H. K., Spinas, G. A., & Berneis, K. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.013540 · Cited by 372
Chiu, S., Sievenpiper, J. L., de Souza, R. J., Cozma, A. I., Mirrahimi, A., Carleton, A. J., Ha, V, Di Buono, M., Jenkins, A. L., Leiter, L. A., et al. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.8 · Cited by 314
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Sucrose, a disaccharide containing glucose and fructose, represents an important source of fructose in the diet.(159,173,174)”
Self-citationFructose metabolism and metabolic disease
Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96702 · Cited by 561
“Prospective studies in which excess fructose is added on top of habitual diets often document spontaneous reductions in other forms of sugar consumption, suggesting strong feedback mechanisms that specifically regulate sugar consumption (141).”
BackgroundDietary Fructose and the Metabolic Syndrome
Taskinen, M.-R., Packard, C. J., & Borén, J. (2019) · Nutrients · doi:10.3390/nu11091987 · Cited by 295
Self-citationDietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Molecular aspects of fructose metabolism and metabolic disease
Herman, M. A., & Birnbaum, M. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.010 · Cited by 290
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
“Fructose induced not only increased expression of APOC3 (111, 113), but also increased hepatic de novo lipogenesis of fatty acids that is an important initiator of NAFLD and overproduction of triglyceride-rich VLDL1 particles (43, 61, 118– 122).”
BackgroundSelf-citationThe role of ChREBP in carbohydrate sensing and NAFLD development
Régnier, M., Carbinatti, T., Parlati, L., Benhamed, F., & Postic, C. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00809-4 · Cited by 101
Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk
Keirns, B. H., Sciarrillo, C. M., Koemel, N. A., & Emerson, S. R. (2021) · Journal of Nutritional Science · doi:10.1017/jns.2021.73 · Cited by 86
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55
Self-citationFructose metabolism and noncommunicable diseases: recent findings and new research perspectives
Tappy, L. (2018) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000460 · Cited by 37
Della Pepa, G., Vetrani, C., Brancato, V., Vitale, M., Monti, S., Annuzzi, G., Lombardi, G., Izzo, A., Tommasone, M., Cipriano, P., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001342 · Cited by 22
Self-citation
Metadata
- Authors
- Taskinen, M. ‐., Söderlund, S., Bogl, L. H., Hakkarainen, A., Matikainen, N., Pietiläinen, K. H., Räsänen, S., Lundbom, N., Björnson, E., Eliasson, B., Mancina, R. M., Romeo, S., Alméras, N., Pepa, G. D., Vetrani, C., Prinster, A., Annuzzi, G., Rivellese, A., Després, J. ‐., & Borén, J.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2017-06-27
- Volume
- 282
- Issue
- 2
- Pages
- 187-201
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2617551124
- Cited by
- 117
- References
- 19
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.